Recce Pharmaceuticals Ltd (ASX:RCE) has reached the halfway mark in dosing participants in its Phase II Acute Bacterial Skin and Skin Structure Infections (ABSSSI) clinical trial. The company has dosed 15 patients in the trial so far, which is seeking to assess the efficacy and safety of its RECCE 327 topical gel (also known as R327G) in relation to treatment of ABSSSI, which includes diabetic foot infections (DFI) and other wound infections. Evidence from the dosing has shown the gel to be safe and well-tolerated across human subjects, with signs of positive antibacterial responses in patient…